Predictivity of dog co-culture model, primary human hepatocytes and HepG2 cells for the detection of hepatotoxic drugs in humans.
暂无分享,去创建一个
Martin L Yarmush | Helga H Gerets | M. Yarmush | E. Novik | A. Parekh | J. MacDonald | C. Delatour | F. Atienzar | H. Gerets | S. Dhalluin | Franck A Atienzar | Eric I Novik | Amit Parekh | Claude Delatour | Alvaro Cardenas | James MacDonald | Stéphane Dhalluin | Alvaro Cárdenas | J. Macdonald
[1] Peter V. Henstock,et al. Cellular imaging predictions of clinical drug-induced liver injury. , 2008, Toxicological sciences : an official journal of the Society of Toxicology.
[2] T. Singer,et al. A label-free, impedance-based real time assay to identify drug-induced toxicities and differentiate cytostatic from cytotoxic effects. , 2013, Toxicology in vitro : an international journal published in association with BIBRA.
[3] R. Beresford,et al. Betaxolol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension. , 1986, Drugs.
[4] S. V. van IJzendoorn,et al. Rho kinase, myosin-II, and p42/44 MAPK control extracellular matrix-mediated apical bile canalicular lumen morphogenesis in HepG2 cells. , 2006, Molecular biology of the cell.
[5] L. Laine,et al. A systematic review of NSAIDs withdrawn from the market due to hepatotoxicity: lessons learned from the bromfenac experience , 2006, Pharmacoepidemiology and drug safety.
[6] Jiri Aubrecht,et al. Predicting safety toleration of pharmaceutical chemical leads: cytotoxicity correlations to exploratory toxicity studies. , 2010, Toxicology letters.
[7] M. Giorgi,et al. Pharmacokinetics and pharmacodynamics of zolpidem after oral administration of a single dose in dogs. , 2012, American journal of veterinary research.
[8] N. Kolatkar,et al. Commentary on ‘case series of liver failure associated with rosiglitazone and pioglitazone’ by Floyd et al. , 2009, Pharmacoepidemiology and drug safety.
[9] E L LeCluyse,et al. Human hepatocyte culture systems for the in vitro evaluation of cytochrome P450 expression and regulation. , 2001, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[10] William M. Lee,et al. Drug‐induced acute liver failure: Results of a U.S. multicenter, prospective study , 2010, Hepatology.
[11] Agustín Lahoz,et al. Development of a multiparametric cell-based protocol to screen and classify the hepatotoxicity potential of drugs. , 2012, Toxicological sciences : an official journal of the Society of Toxicology.
[12] A. Brown,et al. A history of the role of the hERG channel in cardiac risk assessment. , 2013, Journal of pharmacological and toxicological methods.
[13] André Guillouzo,et al. The human hepatoma HepaRG cells: a highly differentiated model for studies of liver metabolism and toxicity of xenobiotics. , 2007, Chemico-biological interactions.
[14] P L Morselli,et al. Comparative pharmacokinetic profile of two imidazopyridine drugs: zolpidem and alpidem. , 1992, Drug metabolism reviews.
[15] D. Greenblatt,et al. Relative Contribution of CYP3A to Amitriptyline Clearance in Humans: In Vitro and In Vivo Studies , 2001, Journal of clinical pharmacology.
[16] K. Hoffmann. Identification of the main urinary metabolites of omeprazole after an oral dose to rats and dogs. , 1986, Drug metabolism and disposition: the biological fate of chemicals.
[17] G. Labbe,et al. Prediction of Liver Injury Induced by Chemicals in Human With a Multiparametric Assay on Isolated Mouse Liver Mitochondria , 2012, Toxicological sciences : an official journal of the Society of Toxicology.
[18] I. Wilson,et al. Characterization and quantification of metabolites of racemic ketoprofen excreted in urine following oral administration to man by 1H-NMR spectroscopy, directly coupled HPLC-MS and HPLC-NMR, and circular dichroism , 2004, Xenobiotica; the fate of foreign compounds in biological systems.
[19] Yvonne Will,et al. Use of micropatterned cocultures to detect compounds that cause drug-induced liver injury in humans. , 2013, Toxicological sciences : an official journal of the Society of Toxicology.
[20] K. Tilmant,et al. Characterization of primary human hepatocytes, HepG2 cells, and HepaRG cells at the mRNA level and CYP activity in response to inducers and their predictivity for the detection of human hepatotoxins , 2012, Cell Biology and Toxicology.
[21] Franco Lombardo,et al. Comprehensive Assessment of Human Pharmacokinetic Prediction Based on In Vivo Animal Pharmacokinetic Data, Part 2: Clearance , 2013, Journal of clinical pharmacology.
[22] Yvonne Will,et al. Evaluation of drugs with specific organ toxicities in organ-specific cell lines. , 2012, Toxicological sciences : an official journal of the Society of Toxicology.
[23] L. Kaminsky,et al. Characterization of human cytochromes P450 involved in theophylline 8-hydroxylation. , 1995, Biochemical pharmacology.
[24] V. Kukes,et al. Experimental and Clinical Pharmacokinetics of Amitryptiline: Comparative Analysis , 2009, Bulletin of Experimental Biology and Medicine.
[25] I. Irwin,et al. Effect of tecarfarin, a novel vitamin K epoxide reductase inhibitor, on coagulation in beagle dogs , 2009, British journal of pharmacology.
[26] Y. Seo,et al. Base excision DNA repair defect in thioredoxin-1 (Trx1)-deficient cells. , 2013, Mutation research.
[27] V. Nosikov,et al. Association of CYP2D6 and ADRB1 genes with hypotensive and antichronotropic action of betaxolol in patients with arterial hypertension , 2007, Fundamental & clinical pharmacology.
[28] Dong Joon Kim,et al. Drug-induced liver injury: present and future , 2012, Clinical and molecular hepatology.
[29] T. Shimizu,et al. Comparisons between in-vitro and in-vivo metabolism of (S)-warfarin: catalytic activities of cDNA-expressed CYP2C9, its Leu359 variant and their mixture versus unbound clearance in patients with the corresponding CYP2C9 genotypes. , 1998, Pharmacogenetics.
[30] E. Rondinelli,et al. CYP2C9 genotypes and the pharmacokinetics of tenoxicam in Brazilians , 2004, Clinical pharmacology and therapeutics.
[31] Dolores Diaz,et al. Applications of cytotoxicity assays and pre-lethal mechanistic assays for assessment of human hepatotoxicity potential. , 2004, Chemico-biological interactions.
[32] P. Vasseur,et al. Comparison of a genomic and a multiplex cell imaging approach for the detection of phospholipidosis. , 2011, Toxicology in vitro : an international journal published in association with BIBRA.
[33] A. Beiderbeck,et al. Commentary on ‘case series of liver failure associated with rosiglitazone and pioglitazone’ by James Floyd et al , 2009, Pharmacoepidemiology and drug safety.
[34] K. Ward,et al. Comparative evaluation of oral systemic exposure of 56 xenobiotics in rat, dog, monkey and human , 2005, Xenobiotica; the fate of foreign compounds in biological systems.
[35] P. Lurie,et al. Case series of liver failure associated with rosiglitazone and pioglitazone , 2009, Pharmacoepidemiology and drug safety.
[36] P Smith,et al. Concordance of the toxicity of pharmaceuticals in humans and in animals. , 2000, Regulatory toxicology and pharmacology : RTP.
[37] J. Remon,et al. Species comparison of enantioselective oral bioavailability and pharmacokinetics of ketoprofen. , 2011, Research in veterinary science.
[38] Albert P. Li,et al. Definition of metabolism-dependent xenobiotic toxicity with co-cultures of human hepatocytes and mouse 3T3 fibroblasts in the novel integrated discrete multiple organ co-culture (IdMOC) experimental system: results with model toxicants aflatoxin B1, cyclophosphamide and tamoxifen. , 2012, Chemico-biological interactions.
[39] Helga Gerets,et al. Determination of phospholipidosis potential based on gene expression analysis in HepG2 cells. , 2006, Toxicological sciences : an official journal of the Society of Toxicology.
[40] Weida Tong,et al. FDA-approved drug labeling for the study of drug-induced liver injury. , 2011, Drug discovery today.
[41] P. Vasseur,et al. The automated micronucleus assay for early assessment of genotoxicity in drug discovery. , 2013, Mutation research.
[42] F. Atienzar,et al. Selection of cytotoxicity markers for the screening of new chemical entities in a pharmaceutical context: a preliminary study using a multiplexing approach. , 2009, Toxicology in vitro : an international journal published in association with BIBRA.
[43] O. Sugita,et al. Drug metabolism by the human hepatoma cell, Hep G2. , 1987, Biochemical and biophysical research communications.
[44] Y. Sugiyama,et al. Prediction of human hepatic clearance from in vivo animal experiments and in vitro metabolic studies with liver microsomes from animals and humans. , 2001, Drug metabolism and disposition: the biological fate of chemicals.
[45] J. Duan,et al. A high throughput in vitro mrp2 assay to predict in vivo biliary excretion , 2012, Xenobiotica; the fate of foreign compounds in biological systems.
[46] T. Guentert,et al. Acceleration of the elimination of tenoxicam by cholestyramine in the dog. , 1986, The Journal of pharmacology and experimental therapeutics.
[47] J. G. Kenna,et al. In Vitro Inhibition of the Bile Salt Export Pump Correlates with Risk of Cholestatic Drug-Induced Liver Injury in Humans , 2012, Drug Metabolism and Disposition.
[48] K. Haasio. Toxicology and safety of COMT inhibitors. , 2010, International review of neurobiology.
[49] M Antonsson,et al. Stereoselective metabolism of omeprazole by human cytochrome P450 enzymes. , 2000, Drug metabolism and disposition: the biological fate of chemicals.
[50] Osamu Okazaki,et al. Human Pharmacokinetic Prediction of UDP-Glucuronosyltransferase Substrates with an Animal Scale-Up Approach , 2011, Drug Metabolism and Disposition.
[51] Melvin E Andersen,et al. Long‐Term Stability of Primary Rat Hepatocytes in Micropatterned Cocultures , 2013, Journal of biochemical and molecular toxicology.
[52] S. Schenker,et al. Effect of short‐term ethanol administration on lorazepam clearance , 1981, Hepatology.
[53] James S MacDonald,et al. Toxicity testing in the 21st century: a view from the pharmaceutical industry. , 2009, Toxicological sciences : an official journal of the Society of Toxicology.
[54] R. Ulrich,et al. Idiosyncratic toxicity: a convergence of risk factors. , 2007, Annual review of medicine.
[55] Yan Li,et al. In vitro approach to assess the potential for risk of idiosyncratic adverse reactions caused by candidate drugs. , 2012, Chemical research in toxicology.
[56] Melvin E. Andersen,et al. Organotypic liver culture models: Meeting current challenges in toxicity testing , 2012, Critical reviews in toxicology.
[57] Meng Li,et al. Identification of interspecies difference in efflux transporters of hepatocytes from dog, rat, monkey and human. , 2008, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[58] F. Atienzar,et al. Evaluation of Impedance-Based Label-Free Technology as a Tool for Pharmacology and Toxicology Investigations , 2013, Biosensors.
[59] M. Yliperttula,et al. Peptide nanofiber hydrogel induces formation of bile canaliculi structures in three-dimensional hepatic cell culture. , 2012, Tissue engineering. Part A.
[60] M. Yarmush,et al. Evaluation of a microfluidic based cell culture platform with primary human hepatocytes for the prediction of hepatic clearance in human. , 2009, Biochemical pharmacology.
[61] K. Maeda,et al. Hepatic Uptake in the Dog: Comparison of Uptake in Hepatocytes and Human Embryonic Kidney Cells Expressing Dog Organic Anion-Transporting Polypeptide 1B4 , 2011, Drug Metabolism and Disposition.
[62] T J Maguire,et al. Design and application of microfluidic systems for in vitro pharmacokinetic evaluation of drug candidates. , 2009, Current drug metabolism.
[63] S. Feinstein,et al. Kinetic cell-based morphological screening: prediction of mechanism of compound action and off-target effects. , 2009, Chemistry & biology.
[64] M. Yarmush,et al. A microfluidic hepatic coculture platform for cell-based drug metabolism studies. , 2010, Biochemical pharmacology.
[65] Etienne Hanon,et al. The Use of Real-Time Cell Analyzer Technology in Drug Discovery: Defining Optimal Cell Culture Conditions and Assay Reproducibility with Different Adherent Cellular Models , 2011, Journal of biomolecular screening.
[66] P. Bernardi,et al. High concordance of drug-induced human hepatotoxicity with in vitro cytotoxicity measured in a novel cell-based model using high content screening , 2006, Archives of Toxicology.
[67] Masashi Yabuki,et al. Evaluation of the Potential for Drug-Induced Liver Injury Based on in Vitro Covalent Binding to Human Liver Proteins , 2009, Drug Metabolism and Disposition.
[68] J. Mckim. Building a Tiered Approach to In Vitro Predictive Toxicity Screening: A Focus on Assays with In Vivo Relevance , 2010, Combinatorial chemistry & high throughput screening.
[69] Nigel Greene,et al. Using an in vitro cytotoxicity assay to aid in compound selection for in vivo safety studies. , 2010, Bioorganic & medicinal chemistry letters.
[70] R. Barkin. Zolpidem Extended-Release: A Single Insomnia Treatment Option for Sleep Induction and Sleep Maintenance Symptoms , 2007, American journal of therapeutics.
[71] K. Olkkola,et al. Midazolam and other benzodiazepines. , 2008, Handbook of experimental pharmacology.
[72] B. Fromenty,et al. Drug-induced toxicity on mitochondria and lipid metabolism: mechanistic diversity and deleterious consequences for the liver. , 2011, Journal of hepatology.